I think 82% in 14 days is probably true, that would be a pretty egregious lie.
If it is true, the problem is instead of partnering with BP and NIH/BARDA like other small caps (VIR, HGEN) to figure out what patient population and dosing LL would work with, NP threw darts at the wall and hoped one would stick.
The question is whether this naively was done to save time, money and partnership costs, or whether BP and the gov't didn't want to cooperate with CytoDyn because of their track record.